AR082930A1 - Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina - Google Patents

Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina

Info

Publication number
AR082930A1
AR082930A1 ARP110103282A ARP110103282A AR082930A1 AR 082930 A1 AR082930 A1 AR 082930A1 AR P110103282 A ARP110103282 A AR P110103282A AR P110103282 A ARP110103282 A AR P110103282A AR 082930 A1 AR082930 A1 AR 082930A1
Authority
AR
Argentina
Prior art keywords
fatty acids
statin
oily mixture
pharmaceutically acceptable
dha
Prior art date
Application number
ARP110103282A
Other languages
English (en)
Spanish (es)
Inventor
Svein Olaf Hustvedt
Preben Houlberg Olesen
Gunnar Berge
Jo Erik Johnsrud Klaveness
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of AR082930A1 publication Critical patent/AR082930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP110103282A 2010-09-08 2011-09-08 Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina AR082930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38107010P 2010-09-08 2010-09-08

Publications (1)

Publication Number Publication Date
AR082930A1 true AR082930A1 (es) 2013-01-16

Family

ID=45811014

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103282A AR082930A1 (es) 2010-09-08 2011-09-08 Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina

Country Status (2)

Country Link
AR (1) AR082930A1 (fr)
WO (1) WO2012032414A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797591A1 (fr) 2009-04-29 2021-03-31 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique stable et procédés d'utilisation associés
BRPI1014405A2 (pt) 2009-04-29 2016-04-05 Amarin Corp Plc composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
EP3072510B1 (fr) * 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Compositions d'ester d'acide gras omega -3
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
HUE053111T2 (hu) 2012-06-29 2021-06-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX2016004487A (es) 2013-10-30 2016-11-10 Banner Life Sciences Llc Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
TR201403323A2 (tr) 2014-03-21 2015-10-21 Ege Ueniversitesi Bilim Teknoloji Uygulama Ve Arastirma Merkezi Ebiltem Rosuvastatinin oral yolla kullanımı için kendiliğinden mikro/nano emülsifiye olabilen ilaç taşıyıcı sistemi.
WO2015185240A1 (fr) * 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (fr) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
WO2016117621A1 (fr) * 2015-01-21 2016-07-28 持田製薬株式会社 Composition auto-émulsifiante d'acides gras ω3
EP3442517A1 (fr) * 2016-04-14 2019-02-20 Lucey, Michael Compositions combinatoires et leurs méthodes d'utilisation
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
WO2022225896A1 (fr) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Procédés de réduction du risque d'insuffisance cardiaque

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
EP1039893B1 (fr) * 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Compositions pharmaceutiques contenant une huile d'acide gras omega-3
WO1999056727A2 (fr) * 1998-05-07 1999-11-11 Elan Corporation, Plc Systemes d'apport de medicament de preconcentre de microemulsion et d'emulsion depourvues de solvant/cosolvant
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
KR20070038553A (ko) * 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
US20100021555A1 (en) * 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
BRPI0607569A2 (pt) * 2005-03-08 2009-09-15 Reliant Pharmaceuticals Inc composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
US7652068B2 (en) * 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
US11395811B2 (en) * 2009-03-09 2022-07-26 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof
JP6116905B2 (ja) * 2009-10-23 2017-04-19 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 脂肪酸油混合物の被覆型カプセル剤および錠剤

Also Published As

Publication number Publication date
WO2012032414A2 (fr) 2012-03-15
WO2012032414A3 (fr) 2012-05-03

Similar Documents

Publication Publication Date Title
AR082930A1 (es) Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
RU2022100434A (ru) Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
AR095182A1 (es) Composiciones de estatinas y ácidos grasos omega-3
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
HRP20210309T1 (hr) Postupci za smanjivanje rizika kardiovaskularnih slučajeva kod pojedinca na statinskoj terapiji uporabom etilestera eikosapentaenoične kiseline
ES2881885T3 (es) Composiciones que comprenden una mezcla de aceites de ácidos grasos que comprende EPA y DHA en forma de ácido libre y un tensioactivo, y procedimientos y usos de las mismas
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
AR085547A1 (es) Composicion compleja oral que comprende ester del acido graso omega-3 y un inhibidor de la hmg-coa reductasa
ES2531599T3 (es) Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales
RU2012116079A (ru) Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
SI2443246T1 (en) Compounds and procedures for lowering triglycerides without increasing the levels of LDL-C in an individual who is simultaneously receiving statin therapy
WO2005089744A3 (fr) Utilisation de docosatrienes, resolvines et leurs analogues stables pour le traitement de maladies des voies respiratoires et de l'asthme
WO2006078457A3 (fr) Utilisation de resolvines pour le traitement des maladies gastro-intestinales
CA2706270A1 (fr) Formulations pharmaceutiques de statines et d'acides gras omega-3 pour encapsulation
US20070032546A1 (en) Novel formulations comprising fenofibrate and a statin, and related methods of treatment
JP2013537185A (ja) 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物
AR101724A1 (es) COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA
JP2007238598A (ja) 脳卒中再発予防用組成物
JP2015143248A5 (fr)
JP2014231513A5 (fr)
JP2014509655A5 (fr)
ES2561207T3 (es) Emulsión grasa para alimentar artificialmente a pacientes gravemente enfermos de cuidados intensivos
WO2009059717A3 (fr) Compositions pharmaceutiques contenant des statines et des dérivés d'acides gras oméga 3 et leurs formulations solides pour administration orale
GB201121503D0 (en) Medicament delivery technology
JP2007238594A (ja) 脳卒中再発予防用組成物

Legal Events

Date Code Title Description
FB Suspension of granting procedure